Orphan Diseases In CNS - Part II Amyotrophic Lateral Sclerosis

Summary

Introduction

The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of pipeline drugs.

Scope

• Scenario based analysis and forecasts of the commercial potential of the ALS market to 2016.
• Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs.
• Strategic recommendations for maximizing the potential of drugs in this niche orphan disease market.
• Indication-specific sales forecasts of marketed and key pipeline drugs to 2016.

Highlights

A lack of new entrants, and the possibility of polytherapy, results in Sanofi-Aventis's Rilutek (riluzole) dominating the market until patent expiry in 2012-13 in Datamonitor's base scenario.

Orphan drug status, rapid uptake following launch, limited risk to the company's share price if drugs fail, and possible indication expansions make long-term investment in ALS a commercially viable option.

A scenario forecast based on the clinical success of rhIGF-1 (recombinant human insulin-like growth factor I) related therapies reveals a potentially lucrative market. However, with a high attrition rate of ALS Phase III clinical trials, and mixed efficacy data in Phase II, the results of currently underway studies will be pivotal.

Reasons to Purchase

• Access the lucrative potential of this underdeveloped neurodegenerative disease therapeutic market.
• Benchmark key late-stage compounds against the current leading therapy Sanofi-Aventis's Rilutek (riluzole).
• Understand the opportunities in this market based on the comments of interviewed key opinion leaders.

Content